Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -45.78%.

  • Heron Therapeutics' EBITDA Margin fell 3115.00% to -45.78% in Q3 2025 from the same period last year, while for Sep 2025 it was -8.78%, marking a year-over-year increase of 1149.00%. This contributed to the annual value of -9.41% for FY2024, which is 7759.00% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' EBITDA Margin is -45.78%, which was down 614.66% from -6.41% recorded in Q2 2025.
  • Heron Therapeutics' EBITDA Margin's 5-year high stood at 8.92% during Q4 2024, with a 5-year trough of -272.37% in Q1 2022.
  • In the last 3 years, Heron Therapeutics' EBITDA Margin had a median value of -25.64% in 2024 and averaged -39.98%.
  • As far as peak fluctuations go, Heron Therapeutics' EBITDA Margin slumped by 6,290bps in 2021, and later skyrocketed by 19,853bps in 2022.
  • Quarterly analysis of 5 years shows Heron Therapeutics' EBITDA Margin stood at -264.58% in 2021, then surged by 19,853bps to -66.04% in 2022, then skyrocketed by 3,476bps to -31.29% in 2023, then soared by 4,020bps to 8.92% in 2024, then crashed by 3,115bps to -45.78% in 2025.
  • Its last three reported values are -45.78% in Q3 2025, -6.41% for Q2 2025, and 6.74% during Q1 2025.